MLL/NN
and/CC
CALM/NN
are/VBP
fused/VBN
to/TO
AF10/NN
in/IN
morphologically/RB
distinct/JJ
subsets/NNS
of/IN
acute/JJ
leukemia/NN
with/IN
translocation/NN
t(10;11)/NN
:/:
both/DT
rearrangements/NNS
are/VBP
associated/VBN
with/IN
a/DT
poor/JJ
prognosis/NN
./.

The/DT
translocation/NN
t(10;11)(p13;q14)/NN
has/VBZ
been/VBN
observed/VBN
in/IN
acute/JJ
lymphoblastic/JJ
leukemia/NN
(/(
ALL/NN
)/)
as/RB
well/RB
as/IN
acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
./.
=====
A/DT
recent/JJ
study/NN
showed/VBD
a/DT
MLL/AF10/NN
fusion/NN
in/IN
all/DT
cases/NNS
of/IN
AML/NN
with/IN
t(10;11)/NN
and/CC
various/JJ
breakpoints/NNS
on/IN
chromosome/NN
11/CD
ranging/VBG
from/IN
q13/NN
to/TO
q23/NN
./.
=====
We/PRP
recently/RB
cloned/VBN
CALM/NN
(/(
Clathrin/NN
Assembly/NN
Lymphoid/JJ
Myeloid/JJ
leukemia/NN
gene/NN
)/)
,/,
the/DT
fusion/NN
partner/NN
of/IN
AF10/NN
at/IN
11q14/NN
in/IN
the/DT
monocytic/JJ
cell/NN
line/NN
U937/NN
./.
=====
To/TO
further/RB
define/VB
the/DT
role/NN
of/IN
these/DT
genes/NNS
in/IN
acute/JJ
leukemias/NNS
,/,
10/CD
cases/NNS
(/(
9/CD
AML/NN
and/CC
1/CD
ALL/NN
)/)
with/IN
cytogenetically/RB
proven/JJ
t(10;11)(p12-14;q13-21)/NN
and/CC
well-characterized/VBD
morphology/NN
,/,
immunophenotype/NN
,/,
and/CC
clinical/JJ
course/NN
were/VBD
analyzed/VBN
./.
=====
Interphase/NN
fluorescence/NN
in/FW
situ/FW
hybridization/NN
(/(
FISH/NN
)/)
was/VBD
performed/VBN
with/IN
2/CD
YACs/NNS
flanking/VBG
the/DT
CALM/NN
region/NN
,/,
a/DT
YAC/NN
contig/NN
of/IN
the/DT
MLL/NN
region/NN
,/,
and/CC
a/DT
YAC/NN
spanning/VBG
the/DT
AF10/NN
breakpoint/NN
./.
=====
Rearrangement/NN
of/IN
at/IN
least/JJS
one/CD
of/IN
these/DT
genes/NNS
was/VBD
detected/VBN
in/IN
all/DT
cases/NNS
with/IN
balanced/JJ
t(10;11)/NN
./.
=====
In/IN
4/CD
cases/NNS
,/,
including/VBG
3/CD
AML/NN
with/IN
immature/JJ
morphology/NN
(/(
1/CD
AML-M0/NN
and/CC
2/CD
AML-M1/NN
)/)
and/CC
1/CD
ALL/NN
,/,
the/DT
signals/NNS
of/IN
the/DT
CALM/NN
YACS/NNS
were/VBD
separated/VBN
in/IN
interphase/NN
cells/NNS
,/,
indicating/VBG
a/DT
translocation/NN
breakpoint/NN
within/IN
the/DT
CALM/NN
region/NN
./.
=====
MLL/NN
was/VBD
rearranged/VBN
in/IN
3/CD
AML/NN
with/IN
myelomonocytic/JJ
differentiation/NN
(/(
2/CD
AML-M2/NN
and/CC
1/CD
AML-M5/NN
)/)
,/,
including/VBG
1/CD
secondary/JJ
AML/NN
./.
=====
In/IN
all/DT
3/CD
cases/NNS
,/,
a/DT
characteristic/JJ
immunophenotype/NN
was/VBD
identified/VBN
(/(
CD4+/JJ
,/,
CD13-/NN
,/,
CD33+/JJ
,/,
CD65s+/JJ
)/)
./.
=====
AF-10/NN
was/VBD
involved/VBN
in/IN
5/CD
of/IN
6/CD
evaluable/JJ
cases/NNS
,/,
including/VBG
1/CD
case/NN
without/IN
detectable/JJ
CALM/NN
or/CC
MLL/NN
rearrangement/NN
./.
=====
In/IN
2/CD
complex/NN
translocations/NNS
,/,
none/NN
of/IN
the/DT
three/CD
genes/NNS
was/VBD
rearranged/VBN
./.
=====
All/DT
cases/NNS
had/VBD
a/DT
remarkably/RB
poor/JJ
prognosis/NN
,/,
with/IN
a/DT
mean/NN
survival/NN
of/IN
9.6/CD
+/-/CC
6.6/CD
months/NNS
./.
=====
For/IN
the/DT
7/CD
AML/NN
cases/NNS
that/WDT
were/VBD
uniformly/RB
treated/VBN
according/VBG
to/TO
the/DT
AMLCG86/92/NN
protocols/NNS
,/,
disease-free/JJ
and/CC
overall/JJ
survival/NN
was/VBD
significantly/RB
worse/JJ
than/IN
for/IN
the/DT
overall/JJ
study/NN
group/NN
(/(
P/NN
=/JJ
.03/CD
and/CC
P/NN
=/JJ
.01/CD
,/,
respectively/RB
)/)
./.
=====
We/PRP
conclude/VBP
that/IN
the/DT
t(10;11)(p13;q14)/NN
indicates/VBZ
CALM/NN
and/CC
MLL/NN
rearrangements/NNS
in/IN
morphologically/RB
distinct/JJ
subsets/NNS
of/IN
acute/JJ
leukemia/NN
and/CC
may/MD
be/VB
associated/VBN
with/IN
a/DT
poor/JJ
prognosis/NN
./.